Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis.

Androdias G, Noroy L, Psimaras D, Birzu C, Pelletier J, Beigneux Y, Branger P, Ciron J, Dananchet Y, Depaz R, Froment Tilikete C, Gignoux L, Grosset-Janin C, Joubert B, Kerschen P, Kwiatkowski A, Lebrun-Frenay C, Maillart E, Maureille A, Nicolas P, Roux T, Marignier R, Vukusic S; as the ICI-SEP group, under the aegis of the Société Francophone de la Sclérose en Plaques (SFSEP).